Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
6.54
-0.13 (-1.95%)
At close: Sep 15, 2026, 4:00 PM EDT
6.55
+0.01 (0.15%)
After-hours: Sep 15, 2026, 6:07 PM EDT
Valneva SE Revenue
Valneva SE had revenue of 34.94M EUR in the quarter ending June 30, 2026, a decrease of -27.71%. This brings the company's revenue in the last twelve months to 142.94M, down -27.19% year-over-year. In the year 2025, Valneva SE had annual revenue of 174.66M with 3.00% growth.
Revenue (ttm)
142.94M EUR
Revenue Growth
-27.19%
P/S Ratio
3.78
Revenue / Employee
230,544 EUR
Employees
620
Market Cap
617.63M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 174.66M | 5.08M | 3.00% |
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| Phathom Pharmaceuticals | 239.66M |
| OmniAb | 38.46M |
| Scribe Therapeutics | 33.30M |
| Allogene Therapeutics | 4.64M |
| Oculis Holding AG | 1.45M |
| Shattuck Labs | 1.00M |
| Altimmune | 31.00K |
VALN News
- 26 days ago - Valneva (VALN) Q2 2026 Earnings Call Transcript - The Motley Fool
- 4 weeks ago - Pfizer, Valneva announce EMA validation for PF-07307405 MAA - TheFly
- 4 weeks ago - Valneva Stock (VLN) Soars Over 20% On Lyme Disease Vaccine Hopes - TipRanks
- 4 weeks ago - Pfizer And Valneva's Lyme Vaccine Clears EMA Review Gate - Nasdaq
- 4 weeks ago - Pfizer, Valneva's Lyme Disease Vaccine Application Validated By EMA - Nasdaq
- 4 weeks ago - Pfizer Inc.: Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - Finanz Nachrichten
- 4 weeks ago - Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - GlobeNewsWire
- 4 weeks ago - Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - Wallstreet:Online